Please ensure Javascript is enabled for purposes of website accessibility

Why Ocugen Stock Is on Fire Today

By George Budwell – Oct 12, 2021 at 9:58AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A positive regulatory development in India is sending the biotech's shares higher today.

What happened

Shares of the clinical-stage biotech Ocugen (OCGN -6.83%) spiked by as much as 22% in premarket trading Tuesday morning. The biotech's stock is moving northward this morning on the news that the COVID-19 vaccine, Covaxin, was granted emergency use approval for children ages 2 to 18 by India's Subject Expert Committee. This vaccine is among the first to receive such a broad emergency use authorization label in the entire world.  

Ocugen is partnered with India's Bharat Biotech to commercialize Covaxin in Canada and the United States. The pair are now waiting on word from the World Health Organization on the vaccine's emergency use application. This critical regulatory decision is expected any day now.  

A toy pig taking flight.

Image source: Getty Images.

So what

Ocugen's goal is to become an important second- to third-tier COVID-19 vaccine player in key developed markets like Canada and the United States. The problem with this strategy is that there are already a surfeit of novel coronavirus vaccines in these high-value territories, with more on the way. Novavax's highly anticipated COVID-19 vaccine known as NVX-CoV2373, for example, should be available in the U.S. early in 2022. As a result, it's not entirely clear how much of a commercial opportunity will be left for late-comers like Ocugen.  

Now what

Is Ocugen's stock a buy on this news? This is an extremely positive regulatory development, to be sure. But it is unlikely to have any bearing on the vaccine's regulatory fate in either Canada or the United States. 

That said, the biotech's shares should still perform well over the long term. If the vaccine can carve out a profitable niche in these increasingly crowded markets where the company owns a commercial license, Ocugen could end up with a healthy and perhaps fairly long-lived revenue stream.  

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
OCGN
$1.50 (-6.83%) $0.11
Novavax Stock Quote
Novavax
NVAX
$17.61 (6.60%) $1.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.